Search Results

Press Releases

TrueBinding Receives FDA IND Go Ahead for Parkinson’s Phase 2A Clinical Trial

November 19, 2024

·

6 min read

TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer’s Disease Treatment

TrueBinding, Inc. announced today that the company has been granted a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food & Drug Administration (FDA).

March 14, 2023

·

3 min read

Biotech Bay

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TrueBinding Inc highlighted the unique method of action (MOA) of TB006, an investigational monoclonal antibody against Galectin-3 (Gal-3) for the treatment of mild to severe AD, at the recent 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.

December 6, 2022

·

9 min read

Drug Development

TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer’s Disease

TrueBinding Inc. today announced top line results from its Phase 1b/2 proof-of-concept trial of TB006, an investigational monoclonal antibody against Galectin-3 for the treatment of mild to severe Alzheimer’s disease (AD) with baseline Mini Mental State Examination (MMSE) scores of 2-24).

November 18, 2022

·

8 min read

Biotech Bay

Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics

Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that TrueBinding, Inc. (“TrueBindi

July 29, 2020

·

2 min read

Biotech Bay

Open-Label Extension Study for Alzheimer’s Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months

TrueBinding, Inc.— a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and other disease areas with great unmet needs— today announced early results from an Open-Label Extension (OLE) study for the use of its TB006 drug in the treatment of Alzheimer’s Disease.

March 28, 2023

·

4 min read

Press Releases

AbTherx Appoints Pallavi Tawde, PhD, as Head of Preclinical R&D Strategy

July 17, 2024

·

3 min read